In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.Q: How does the new indication expand the eligible patient population?
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trialsdoi:10.1016/j.atherosclerosis.2020.10.050P.B. DuellM. BanachA.L. CatapanoU. Laufs...
bempedoic acid is a desirable alternative for some patient groups, particularly those who may not respond well to or tolerate conventional statin treatments. Bempedoic acid’s market demand and positioning within personalized healthcare frameworks are enhanced by healthcare professionals’ consideration of ...
FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALSdoi:10.1016/S0735-1097(20)32543-2Erik S. G StroesHarold BaysMaciej BanachAlberico Catapano...
In this case study, we describe a patient with HeFH who had a prior excellent response to statin but unable to take the same, and a less than expected response to PCSK9i, in whom initiation of bempedoic acid led to a substantial reduction of LDL-C. Our findings suggest that patients ...
Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trialsdoi:10.1016/j.jacl.2020.05.056Erik StroesHarold BaysMaciej BanachAlberico Catapano
In the present review, the biochemical and pharmacological characteristics of bempedoic acid are discussed. An overview of the clinical data that support its use in the management of the cardiovascular patient and its allocation in the lipid-lowering scenario will be also provided. Keywords: low-...